FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912578499> ?p ?o ?g. }

• W2912578499 endingPage "e346" @default.
• W2912578499 startingPage "e337" @default.
• W2912578499 abstract "BackgroundPneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal disease caused by vaccine serotypes, but the burden of pneumococcal disease in low-income and middle-income countries is dominated by pneumonia, most of which is non-bacteraemic. We examined the effect of 10-valent PCV on the incidence of pneumonia in Kenya.MethodsWe linked prospective hospital surveillance for clinically-defined WHO severe or very severe pneumonia at Kilifi County Hospital, Kenya, from 2002 to 2015, to population surveillance at Kilifi Health and Demographic Surveillance System, comprising 45 000 children younger than 5 years. Chest radiographs were read according to a WHO standard. A 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PCV10) was introduced in Kenya in January, 2011. In Kilifi, there was a three-dose catch-up campaign for infants (aged <1 year) and a two-dose catch-up campaign for children aged 1–4 years, between January and March, 2011. We estimated the effect of PCV10 on the incidence of clinically-defined and radiologically-confirmed pneumonia through interrupted time-series analysis, accounting for seasonal and temporal trends.FindingsBetween May 1, 2002 and March 31, 2015, 44 771 children aged 2–143 months were admitted to Kilifi County Hospital. We excluded 810 admissions between January and March, 2011, and 182 admissions during nurses' strikes. In 2002–03, the incidence of admission with clinically-defined pneumonia was 2170 per 100 000 in children aged 2–59 months. By the end of the catch-up campaign in 2011, 4997 (61·1%) of 8181 children aged 2–11 months had received at least two doses of PCV10 and 23 298 (62·3%) of 37 416 children aged 12–59 months had received at least one dose. Across the 13 years of surveillance, the incidence of clinically-defined pneumonia declined by 0·5% per month, independent of vaccine introduction. There was no secular trend in the incidence of radiologically-confirmed pneumonia over 8 years of study. After adjustment for secular trend and season, incidence rate ratios for admission with radiologically-confirmed pneumonia, clinically-defined pneumonia, and diarrhoea (control condition), associated temporally with PCV10 introduction and the catch-up campaign, were 0·52 (95% CI 0·32–0·86), 0·73 (0·54–0·97), and 0·63 (0·31–1·26), respectively. Immediately before PCV10 was introduced, the annual incidence of clinically-defined pneumonia was 1220 per 100 000; this value was reduced by 329 per 100 000 at the point of PCV10 introduction.InterpretationOver 13 years, admissions to Kilifi County Hospital for clinically-defined pneumonia decreased sharply (by 27%) in association with the introduction of PCV10, as did the incidence of radiologically-confirmed pneumonia (by 48%). The burden of hospital admissions for childhood pneumonia in Kilifi, Kenya, has been reduced substantially by the introduction of PCV10.FundingGavi, The Vaccine Alliance and Wellcome Trust. Pneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal disease caused by vaccine serotypes, but the burden of pneumococcal disease in low-income and middle-income countries is dominated by pneumonia, most of which is non-bacteraemic. We examined the effect of 10-valent PCV on the incidence of pneumonia in Kenya. We linked prospective hospital surveillance for clinically-defined WHO severe or very severe pneumonia at Kilifi County Hospital, Kenya, from 2002 to 2015, to population surveillance at Kilifi Health and Demographic Surveillance System, comprising 45 000 children younger than 5 years. Chest radiographs were read according to a WHO standard. A 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PCV10) was introduced in Kenya in January, 2011. In Kilifi, there was a three-dose catch-up campaign for infants (aged <1 year) and a two-dose catch-up campaign for children aged 1–4 years, between January and March, 2011. We estimated the effect of PCV10 on the incidence of clinically-defined and radiologically-confirmed pneumonia through interrupted time-series analysis, accounting for seasonal and temporal trends. Between May 1, 2002 and March 31, 2015, 44 771 children aged 2–143 months were admitted to Kilifi County Hospital. We excluded 810 admissions between January and March, 2011, and 182 admissions during nurses' strikes. In 2002–03, the incidence of admission with clinically-defined pneumonia was 2170 per 100 000 in children aged 2–59 months. By the end of the catch-up campaign in 2011, 4997 (61·1%) of 8181 children aged 2–11 months had received at least two doses of PCV10 and 23 298 (62·3%) of 37 416 children aged 12–59 months had received at least one dose. Across the 13 years of surveillance, the incidence of clinically-defined pneumonia declined by 0·5% per month, independent of vaccine introduction. There was no secular trend in the incidence of radiologically-confirmed pneumonia over 8 years of study. After adjustment for secular trend and season, incidence rate ratios for admission with radiologically-confirmed pneumonia, clinically-defined pneumonia, and diarrhoea (control condition), associated temporally with PCV10 introduction and the catch-up campaign, were 0·52 (95% CI 0·32–0·86), 0·73 (0·54–0·97), and 0·63 (0·31–1·26), respectively. Immediately before PCV10 was introduced, the annual incidence of clinically-defined pneumonia was 1220 per 100 000; this value was reduced by 329 per 100 000 at the point of PCV10 introduction. Over 13 years, admissions to Kilifi County Hospital for clinically-defined pneumonia decreased sharply (by 27%) in association with the introduction of PCV10, as did the incidence of radiologically-confirmed pneumonia (by 48%). The burden of hospital admissions for childhood pneumonia in Kilifi, Kenya, has been reduced substantially by the introduction of PCV10." @default.
• W2912578499 created "2019-02-21" @default.
• W2912578499 creator A5008358235 @default.
• W2912578499 creator A5008950900 @default.
• W2912578499 creator A5013169634 @default.
• W2912578499 creator A5017355721 @default.
• W2912578499 creator A5017426437 @default.
• W2912578499 creator A5020562642 @default.
• W2912578499 creator A5027864452 @default.
• W2912578499 creator A5028638805 @default.
• W2912578499 creator A5028680785 @default.
• W2912578499 creator A5029215262 @default.
• W2912578499 creator A5031215432 @default.
• W2912578499 creator A5041775046 @default.
• W2912578499 creator A5042729842 @default.
• W2912578499 creator A5047675545 @default.
• W2912578499 creator A5047932989 @default.
• W2912578499 creator A5048601925 @default.
• W2912578499 creator A5049994926 @default.
• W2912578499 creator A5067318365 @default.
• W2912578499 creator A5072332085 @default.
• W2912578499 creator A5072934006 @default.
• W2912578499 creator A5077131295 @default.
• W2912578499 creator A5078024027 @default.
• W2912578499 creator A5080005270 @default.
• W2912578499 creator A5081629035 @default.
• W2912578499 creator A5090868698 @default.
• W2912578499 creator A5091582777 @default.
• W2912578499 date "2019-03-01" @default.
• W2912578499 modified "2023-10-16" @default.
• W2912578499 title "Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis" @default.
• W2912578499 cites W1970041510 @default.
• W2912578499 cites W1984874957 @default.
• W2912578499 cites W2039251425 @default.
• W2912578499 cites W2049386698 @default.
• W2912578499 cites W2051453885 @default.
• W2912578499 cites W2069342251 @default.
• W2912578499 cites W2074027741 @default.
• W2912578499 cites W2075357156 @default.
• W2912578499 cites W2093536091 @default.
• W2912578499 cites W2097129414 @default.
• W2912578499 cites W2101661555 @default.
• W2912578499 cites W2113559481 @default.
• W2912578499 cites W2115456658 @default.
• W2912578499 cites W2122598469 @default.
• W2912578499 cites W2123644769 @default.
• W2912578499 cites W2127841934 @default.
• W2912578499 cites W2136544583 @default.
• W2912578499 cites W2170190476 @default.
• W2912578499 cites W2400939738 @default.
• W2912578499 cites W2520955699 @default.
• W2912578499 cites W2543759215 @default.
• W2912578499 cites W2549697535 @default.
• W2912578499 cites W2568482737 @default.
• W2912578499 cites W2621893872 @default.
• W2912578499 cites W2884902191 @default.
• W2912578499 cites W2938160079 @default.
• W2912578499 doi "https://doi.org/10.1016/s2214-109x(18)30491-1" @default.
• W2912578499 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6379823" @default.
• W2912578499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30784634" @default.
• W2912578499 hasPublicationYear "2019" @default.
• W2912578499 type Work @default.
• W2912578499 sameAs 2912578499 @default.
• W2912578499 citedByCount "43" @default.
• W2912578499 countsByYear W29125784992018 @default.
• W2912578499 countsByYear W29125784992019 @default.
• W2912578499 countsByYear W29125784992020 @default.
• W2912578499 countsByYear W29125784992021 @default.
• W2912578499 countsByYear W29125784992022 @default.
• W2912578499 countsByYear W29125784992023 @default.
• W2912578499 crossrefType "journal-article" @default.
• W2912578499 hasAuthorship W2912578499A5008358235 @default.
• W2912578499 hasAuthorship W2912578499A5008950900 @default.
• W2912578499 hasAuthorship W2912578499A5013169634 @default.
• W2912578499 hasAuthorship W2912578499A5017355721 @default.
• W2912578499 hasAuthorship W2912578499A5017426437 @default.
• W2912578499 hasAuthorship W2912578499A5020562642 @default.
• W2912578499 hasAuthorship W2912578499A5027864452 @default.
• W2912578499 hasAuthorship W2912578499A5028638805 @default.
• W2912578499 hasAuthorship W2912578499A5028680785 @default.
• W2912578499 hasAuthorship W2912578499A5029215262 @default.
• W2912578499 hasAuthorship W2912578499A5031215432 @default.
• W2912578499 hasAuthorship W2912578499A5041775046 @default.
• W2912578499 hasAuthorship W2912578499A5042729842 @default.
• W2912578499 hasAuthorship W2912578499A5047675545 @default.
• W2912578499 hasAuthorship W2912578499A5047932989 @default.
• W2912578499 hasAuthorship W2912578499A5048601925 @default.
• W2912578499 hasAuthorship W2912578499A5049994926 @default.
• W2912578499 hasAuthorship W2912578499A5067318365 @default.
• W2912578499 hasAuthorship W2912578499A5072332085 @default.
• W2912578499 hasAuthorship W2912578499A5072934006 @default.
• W2912578499 hasAuthorship W2912578499A5077131295 @default.
• W2912578499 hasAuthorship W2912578499A5078024027 @default.
• W2912578499 hasAuthorship W2912578499A5080005270 @default.
• W2912578499 hasAuthorship W2912578499A5081629035 @default.
• W2912578499 hasAuthorship W2912578499A5090868698 @default.
• W2912578499 hasAuthorship W2912578499A5091582777 @default.
• W2912578499 hasBestOaLocation W29125784991 @default.

• next